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Abstract: 260/250 words 
Background 
The World Health Organization aims to eliminate the hepatitis C virus (HCV) as a public health threat 
by 2030. Injecting drug use (IDU) is an important risk factor for HCV transmission, but the 
contribution to country-level and global epidemics is unknown. We estimated the contribution of 
IDU-associated risk to HCV epidemics at country and global levels. 
 
Methods 
A dynamic, deterministic HCV transmission model simulated country-level HCV epidemics among 
people who inject drugs (PWID) and the general population. Each country’s model was calibrated 
using country-specific data from UN datasets and systematic reviews on the prevalence of HCV and 
IDU. The population attributable fraction (tPAF) of HCV transmission associated with IDU was 
estimated, defined here as the percentage of HCV infections prevented if additional HCV 
transmission due to IDU was removed between 2018-2030. 
Findings 
The model included 88 countries (85% of the global population). The model predicted 0.2% of 
individuals were PWID in 2017 and 8% of prevalent HCV infections were among people who recently 
injected drugs. Globally, if elevated HCV transmission risk among PWID was removed, an estimated 
43% (95% credibility interval [CrI]: 25%-67%), the tPAF, of incident HCV infections would be 
prevented from 2018-2030, varying regionally. The tPAF was higher (79%, CrI: 57%-97%) in high-
income countries than low and middle-income countries (38%, CrI: 24%-64%) and was associated 
with the percentage of a country’s prevalent infections that are among PWID. 
Interpretation 
Unsafe injecting practices among PWID contribute substantially to incident infections globally; any 
intervention that can reduce transmission among PWID will have a pronounced effect on country 
level incidence.  
Funding 
NIHR 
 
  
  
Research in context 
Evidence before this study 
To gather literature on the burden of the hepatitis C virus (HCV) epidemic that was due to injecting 
drug use, searches were performed in Pubmed with the terms (“IDU” or “PWID” or “IVDU” or 
“injection drug” or “injecting drug” or “intravenous drug” or “people who inject drugs”) and 
(“burden” or “PAF” or “Population attributable”) and (“HCV” or “hepatitis C”). Four previous papers 
were found that have investigated the importance of injecting drug use to the HCV burden nationally 
or globally in terms of infection or disease. In 2016 a modelling analysis by Degenhardt et al 
estimated that around 39% of the 2013 HCV disease burden in terms of disability adjusted life years 
(DALYs) was due to injecting drug use, whilst a 2018 analysis by Grebely et al calculated that 8.5% of 
prevalent HCV infections globally were among people with recent injecting drug use. Nationally, a 
2013 study by Vriend et al estimated that around 28% of current infections in the Netherlands were 
through injecting drug use, whilst a 2018 study by Harris et al estimated that around 34% of the UK’s 
current HCV burden was among current injectors. 
Added value of this study 
This is the first study to quantify the contribution of injecting drug use to overall levels of HCV 
transmission at country, regional, and global levels. Eighty-eight countries, comprising 85% of the 
global population, were modelled. Globally, if the HCV transmission risk due to unsterile needle and 
syringe sharing among people who currently inject drugs was removed, then our modelling suggests 
that 43% of incident HCV infections would be prevented between 2018 and 2030, varying from 14% 
in Sub-Saharan Africa and South Asia to 96% in Eastern Europe. For high-income countries, the 
percentage of incident HCV infections that would be prevented is around twice as high (79%) as in 
low or middle-income countries (38%). The percentage of the country’s prevalent infections that are 
among PWID is strongly related to the proportion of incident HCV infections prevented when the 
transmission risk due injecting drug use is removed. 
Implications of all the available evidence 
This modelling indicates the substantial contribution that injecting drug use makes to the global HCV 
epidemic. For many settings, scaling up HCV prevention and treatment interventions for people who 
inject drugs, including needle and syringe provision and opioid substitution therapy, will be essential 
to meet World Health Organization 2030 elimination targets. 
  
  
Introduction 
Hepatitis C virus (HCV) is a bloodborne virus that causes substantial morbidity1. Globally, it is 
estimated that over 70 million individuals are chronically infected with HCV, with around 400,000 
HCV-related deaths occurring annually1,2. The World Health Organization (WHO) has set ambitious 
targets to eliminate hepatitis C virus (HCV) as a public health threat by 20303, which involve reducing 
incident infections by 80% from their 2015 levels and reducing HCV-related mortality by 65%3. 
Injecting drug use (IDU) is an important risk factor for the transmission of bloodborne viruses, due to 
sharing of used needles and injecting equipment4. Although HCV prevalence amongst people who 
inject drugs (PWID) is generally high (>30%)4, the prevalence of IDU in most countries is low (<1% of 
adults)4. It is therefore generally assumed that IDU is usually only an important contributor to HCV 
transmission in low prevalence settings, mainly high-income countries (HICs) in Europe, Australasia, 
and North America5. Conversely, its role in low and middle-income countries (LMICs), some of which 
have higher HCV prevalence2, is thought to be small6. In these settings, it is assumed that 
transmission is driven by other risk factors, such as unsterile medical injections, other medical 
procedures, unscreened blood transfusions, and community risks (e.g. barbering, tattooing, and 
body piercings)5-7. 
Two recent analyses attempted to quantify the role of IDU to the transmission and disease burden of 
HCV8,9. These estimated two very distinct measures; the proportion of global prevalent HCV 
infections that are amongst people who have recently injected drugs, around 8.5%8, and the 
proportion of the global HCV morbidity burden attributable to IDU, roughly 39%9. Neither measured 
the full and future HCV transmissions resulting from IDU and neither accounted for current or ex-
injectors infected due to IDU conferring additional transmission risk through iatrogenic or other 
routes. This transmission can be through routes such as tattooing in prisons10, mother-to-child 
transmission11, needlestick injuries to healthcare workers12, and general access to healthcare leading 
to iatrogenic transmission13.  
Policy-makers should plan the most efficient use of resources to prevent and treat HCV infections in 
response to the WHO’s 2030 elimination targets3. To do this, it is important to understand the future 
role of IDU to HCV transmission. To address this knowledge gap, we use country-specific HCV 
transmission modelling to estimate the contribution of IDU to HCV transmission at the country-level, 
regionally, and globally. We estimate the proportion of HCV infections that would be prevented from 
2018-2030 if HCV transmission due to injecting risks were removed.  
 
  
  
Methods 
Model description 
We used a dynamic, deterministic HCV transmission model to simulate country-level HCV epidemics 
among the general population and PWID, incorporating age distributions, population growth, and 
HCV progression. We modelled three age-groups: 0–14, 15–34, and ≥35–year olds, with the middle 
age group selected to approximate the age range that individuals start injecting, using information 
from Degenhardt et al. New-borns enter the youngest group and then progress through the age-
groups. We stratified adults (≥15 years) into individuals who had never injected drugs, PWID 
(defined as people who currently inject drugs), and people who previously injected drugs 
(supplementary figure 1, appendix p4). Only young adults (15–34-year olds) were assumed to initiate 
injecting. All PWID ceased to inject at a fixed rate to become people who previously injected drugs.  
Most individuals enter the model susceptible to infection. HCV transmission occurs due to IDU 
among PWID, or otherwise from risk-factors representing medical and community risk-factors for all 
people. Mother-to-child transmission of HCV results in some individuals entering the model 
chronically infected. This occurs at a rate dependent on the number of HCV-infected women of 
childbearing age (modelled as 15-34) and their HIV co-infection prevalence14. Once infected, 
individuals either spontaneously clear their infection, and become susceptible again, or develop life-
long chronic infection. Those chronically infected progress through different HCV-related disease 
stages (chronic, compensated, and decompensated cirrhosis). Individuals with decompensated 
cirrhosis have increased HCV-related mortality. 
Modelled HCV treatment occurs at historical rates that are carried forward from 2017. A proportion 
of those treated achieve a sustained virologic response (SVR) and become susceptible to re-
infection, which occurs at the same rate as primary infection. The rest remain chronically infected. 
Following successful treatment, no further disease progression occurs if individuals had chronic 
infection15. Continued slower progression occurs among those with cirrhosis15. All individuals die at 
age-specific death rates. Current PWID experience elevated death from drug-related mortality16. The 
supplementary materials describe further model details. 
Model parameterization  
Country-specific data from recent systematic reviews, particularly Blach et al2 and Degenhardt et al4, 
and United Nations (UN) datasets were used to parameterize and calibrate the model, including data 
on the prevalence of HCV among PWID and the general population, estimates for the population 
proportion of PWID, and data on population growth rates and age distributions. Supplementary 
table 4 (appendix p10) gives details on the sources of the data used. Supplementary Table 10 
(appendix p39) gives estimates for country-level HCV prevalences and the population proportion of 
PWID. The study by Degenhardt et al, from which most estimates of injecting population sizes were 
taken, states that they preferentially selected size and HCV prevalence estimates that defined 
current injectors as individuals that have injected drugs in the previous 12 months. However, other 
estimates using alternative definitions (eg. injecting in the last 6 months) were still included in the 
review in the absence of the preferred definition. For country-level HCV prevalence estimates, HCV 
antibody prevalence was taken from the reviews, and was adjusted using region-specific viraemic 
rates to estimate the prevalence of chronic infection in the survey year17. Historical treatment 
  
numbers were taken from various sources, which are described in the supplementary materials. All 
key parameters had uncertainty associated with them, with bounds generally obtained directly from 
studies. Where bounds were unavailable for prevalence inputs, ±33% uncertainty bounds were 
applied, which equates to the median level of uncertainty for those parameters that did have 
bounds - this was to avoid ascribing too much certainty to those estimates with no uncertainty 
bounds. Parameter estimates, and country-level data are given in supplementary tables 1-2 and 6-9, 
which provide further information on model parameterization.  
Model calibration 
The model was calibrated to 88 countries, including 85% of the global population, 92% of the 
population in HICs, and 83% in LMICs. Only 43% of the population in sub-Saharan Africa was covered 
by the model, 62% in the Middle East and North Africa and 64% in Latin America, whilst ≥95% of the 
population in the remaining regions were modelled.  
A four-step calibration method, using different sub-models, was used to calibrate the overall model 
for each country, from 1990 onwards. For each step, we randomly sampled various model 
parameters and calibration data from their uncertainty bounds, and then estimated other unknown 
model parameters through calibrating specific sub-models using the nonlinear least-squares fitting 
function in Matlab version R2018a (the mathematical modelling software). This process of 
calibration builds on previous published work from our group18,19, using methods similar to those 
used by others20,21. Samples were generated until 1000 full model fits were obtained for each 
country. Runs were rejected if they could not fit the calibration data within ±33%, so allowing the 
same level of uncertainty as for the model parameters. To ensure the quality of the calibration, the 
resulting fits were checked and compared with the target values, with the average error being in 
general less than 0.0001%. 
The first stage of the calibration process fit a population growth sub-model (sub-model 1) to 
calculate country-specific population growth rates between 1990 and 2015, fitting to population 
sizes in 2015. In the next stage, this model was then adapted to include age demographics (sub-
model 2) to estimate age-specific death rates in 2015. These death rates were estimated by fitting 
sub-model 2 to data on the proportion of the population in age-groups 0-14, 15-34, and ≥35 years. 
For the third stage, this model was then further adapted to include IDU (sub-model 3). The rates that 
young adults initiate IDU was estimated by fitting sub-model 3 to the country’s proportion of adults 
that are PWID. Lastly, the model was again extended to include HCV infection (sub-model 4, i.e. the 
full model). Sampled and fitted parameters from the previous sub-models were used in the full 
model to estimate HCV transmission rates for IDU and the general population. We did this by fitting 
the full model to available chronic prevalence estimates among PWID and the general population for 
a specific year for each country (sub-model 4). The calibration methods are described fully in the 
supplementary materials. 
Given improved blood bank screening22 and a reduction in the re-use of medical syringes23 over 
recent years, the HCV epidemics for each country were assumed to be in slow decline (about 1% 
annually), consistent with a recent review2. This was calibrated by seeding the initial epidemic in 
1990 at a prevalence that was higher than the available survey estimate that was being calibrated to 
but with considerable uncertainty (no decrease to 150% of this decrease). The HCV prevalence 
among PWID was assumed to be stable between 1990 and the year of the survey estimate for all 
  
countries due to evidence from a recent systematic review4. The population proportion of PWID 
among adults was also assumed to be stable between 1990 and the year of the estimate, except for 
Sub-Saharan African and Eastern European countries where we assumed recent increases (from 
1990 onwards) in IDU as suggested by available data24,25. The rationale underlying these assumptions 
are discussed in detail in the supplementary materials and tested in various sensitivity analyses.  
Model analyses 
The calibrated models for each country were used to project the HCV epidemic for 12 years up to 
2030, defined as the baseline projections for each country. To investigate the degree to which HCV 
transmission is driven by risks associated with IDU, the population attributable fraction (tPAF) of HCV 
transmission (incidence) due to IDU in each country, regionally, and globally, was estimated. To do 
this, the baseline model fits for each country were re-run with the transmission risk due to IDU set to 
zero from 2018 onwards. For each paired parameter set, the tPAF was estimated over 1 and 12 years 
as the relative reduction in the overall number of HCV infections over that period from setting the 
transmission risk due to IDU to zero (from 2018), compared to the baseline projections. The 
projections for all paired parameter sets from each country were averaged to produce country-
specific estimates, which were then combined to produce regional and global estimates with the 
average tPAFs for each country weighted by that country’s relative burden of HCV compared to the 
regional or global burden. The variation across the different model fits for each country were used to 
produce 95% credibility intervals (CrI). 
Sensitivity analyses investigated the effect on the tPAF estimates of: (a) general population HCV 
prevalence being stable, rather than declining from 1990; (b) HCV prevalence among PWID 
decreasing at the same rate as the general population HCV prevalence, rather than being stable; (c) 
the proportion of adults that are PWID in 1990 being stable in Eastern Europe and Sub-Saharan 
Africa, rather than increasing; (d) the same annual HCV treatment numbers, but with half the 
treatment rate among PWID and double the treatment rate among people with cirrhosis; (e) the rate 
of initiating injecting in USA increasing 2.9-fold from 2010 onwards, to capture the recent opioid 
epidemic26; (f) varying the temporal changes in general population HCV prevalence by region; and (g) 
treating all infected PWID in 2018 as well as removing the additional transmission rate among PWID. 
We used generalised linear regression models to determine what country-level factors are 
associated with the tPAF of HCV due to risks associated with IDU. The 12-year tPAF was logit 
transformed (log(tPAF/1-tPAF)) as it is a proportion, and was regressed on the covariates for the 
percentage of the adult population that are PWID, HCV prevalence among PWID, HCV prevalence 
among the general population, the injecting duration of PWID in the country, the percentage of the 
country’s prevalent infections that are among PWID, and the World Bank Gross National Income 
(GNI) per capita (which could possibly act as a confounder for the amount of spending on a country’s 
healthcare system) – all from 2017. The non-linear association between the tPAF of HCV due to IDU 
and the percentage of the country’s prevalent infections that are among PWID was plotted using a 
fractional polynomial model. 
Role of the funding source 
The funders had no role in the study design, or in the collection, analysis, and interpretation of data; 
or in the writing of the report; or in the decision to submit the paper for publication. The 
  
corresponding author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
  
Results 
The model was successfully calibrated for 88 countries, as shown in Figure 1. For the countries 
simulated, the model predicts that in 2017 0.23% (95% CrI: 0.16%-0.31%) of the global population 
are PWID and 8% (95% CrI: 5%-12%) of all HCV infections are among people who currently inject 
drugs. 
Table 1 and figure 2 show the regional and global estimates of the tPAF of IDU-associated risks to 
HCV transmission, with the 12-year country-level tPAFs shown in figures 3 and 4 and supplementary 
table 10 (appendix p39). Globally, the model estimates 43% (95% CrI: 25%-67%) of all new HCV 
infections could be prevented over 12-years if the heightened HCV risk associated with IDU was 
removed, varying from 14% (95% CrI: 2%-43%) in Sub-Saharan Africa to 96% (95% CrI: 69%-99%) in 
Eastern Europe. The 12-year tPAFs of IDU to HCV are over 50% for five other global regions: Western 
Europe, North America, Latin America, Australasia, and East and Southeast Asia, while they are less 
than 50% for Central Asia, South Asia, and Middle East and North Africa. The contribution of IDU to 
HCV transmission is greatest in HICs, where 79% (95% CrI: 57%-97%) of new HCV infections could be 
prevented if the transmission risk due to IDU was removed, compared to 38% (95% CrI: 24%-64%) in 
LMICs. The 1-year global tPAF for IDU over 2018-19, 39% (95% CrI: 21%-64%), is slightly lower than 
the 12-year tPAF (2018-2030).  
Supplementary tables 11 and 12 (appendix p42 and p44, respectively) show the results of various 
sensitivity analyses, with the most important changes indicating the tPAF could be lower, 33% (95% 
CrI: 20%-54%), if the HCV prevalence trends among the general population were assumed to be 
stable instead of decreasing, or 30% (95% CrI: 15%-51%) if trends varied by region. Sensitivity 
analyses also showed that the tPAF for USA rose from 67% (95% CrI: 41%-100%) in the baseline 
model to 85% (95% CrI: 62%-100%) when we assumed an increasing epidemic of IDU since 2010, 
This increase occurs due to there being 2.9 times more PWID in the modified model during the 
analysis period than for the baseline model. The sensitivity analyses where we separately assumed 
(i) a decreasing HCV prevalence among PWID, (ii) the population proportion of PWID in Eastern 
Europe and Sub-Saharan Africa was stable from 1990 (rather than increasing), (iii) treatment rates 
are halved among PWID and doubled among people with cirrhosis, did not alter the global tPAF 
estimate. Lastly, supplementary table 13 (appendix p45) shows that the global tPAF increases to 46% 
(95% CrI: 26%-65%) if the heightened burden of HCV among PWID was also removed as well as their 
elevated transmission risk. 
Figure 5 shows there is a strong, positive association between the 12-year tPAF for each country and 
the percentage of the country’s prevalent infections that are among PWID. In univariable regression 
analyses (table 2), the logit transformed country-level tPAF increases linearly with the percentage of 
a country’s prevalent infections that are among PWID, the country’s GNI coefficient, HCV prevalence 
among PWID, and the population percentage of PWID. In the multivariable model, only the 
percentage of a country’s prevalent infections that are among PWID was associated with higher 12-
year tPAF.   
  
Discussion 
Despite PWID comprising less than 0.5% of the global adult population and only contributing 8% of 
prevalent infections, removing the transmission risk due to IDU could prevent nearly one-half (43%) 
of all new HCV infections globally from 2018-2030. This varied by country and regions. In sub-
Saharan Africa, where the epidemic is thought to be driven by medical transmission27, just over one-
tenth of infections are due to the elevated risk associated with IDU, whereas in Eastern Europe it is 
over nine-tenths of infections. In HICs, about twice as many infections (79%) would be prevented 
from removing the transmission risk due to IDU than in LMICs (38%). Interestingly, the percentage of 
a country’s prevalent infections that are among PWID is strongly, positively associated with the tPAF, 
as this takes into account the size of the PWID population as well as the prevalence of HCV among 
them. For example, if 5% of the country’s prevalent infections are among current injectors then the 
estimated tPAF is 48%, which increases to 70% if 10% of prevalent infections are among PWID.  
Comparison with other literature 
To our knowledge, no paper has estimated the future contribution of IDU-related risk to HCV 
transmission at a global level. Two papers have estimated the current contribution of IDU to the 
global burden of HCV infection or disease8,9, but neither accounted for the chain of transmission that 
can occur in the general population due to individuals that were infected through IDU. Degenhardt 
et al estimated that 39% of disability adjusted life years (DALYs) for HCV in 2013 were due to IDU9, 
consistent with the magnitude of our estimate despite using a very different outcome and 
methodology. Grebely et al. calculated 8.5% of all prevalent HCV infections globally were among 
PWID, comparable to our estimate of 8% for prevalent infections in 20178. Grebely et al.’s estimate 
is useful for guiding screening and treatment campaigns but does not address the importance of IDU 
to future HCV transmission. Otherwise, global modelling by Blach et al. simulated the overall HCV 
epidemics in different countries but did not model person-to-person HCV transmission or the role of 
IDU2. Lastly, our results appear to broadly agree with national estimates of the burden of HCV due to 
injecting risks in the Netherlands and the UK,28,29 with these analyses suggesting that 28% of current 
infections in the Netherlands are due to IDU28, within the credibility intervals of our estimate (3-
31%), and 34% of the UK’s current HCV burden is among PWID29, very similar to our projections 
(33%, 95% CrI: 24%-42%).  
Strengths and limitations 
Our modelling is comprehensive in coverage as the analysis uses data from HCV epidemics in 88 
countries, comprising 85% of the world’s population. We account for the role of heightened risk 
among PWID in these HCV epidemics, and incorporate country-level demographic information, 
population growth, and vertical transmission. Importantly, we account for all incident infections that 
result from individuals infected due to IDU, and the effect this has on the general population’s HCV 
incidence and prevalence. This enables us to more accurately estimate the role that IDU has on the 
overall epidemics in each country. Despite this, our analysis has limitations. 
The data on the prevalence of IDU, and the prevalence of HCV amongst PWID and the general 
population were variable in quality, possibly impacting on our results. For the former two quantities 
this is partly due to the illicit nature of IDU, which makes PWID a difficult population to study and to 
enumerate accurately. Data for these three quantities came from existing systematic reviews, and 
  
we modelled all countries that had an estimate for each. This meant that for some data estimates it 
was unclear how they were compiled, some were old, and some were uncertain.  
Taking data from disparate sources means some of country-level tPAF estimates may be imprecise. 
However, it is hard to quantify how this affects our results without additional data. Data-quality 
scores are shown in supplementary table 8, with 46% of countries having a low scored general 
population HCV prevalence estimate, and 20% and 39% of country estimates for HCV prevalence 
among PWID and the proportion of adults that inject drugs, respectively, having low scores. 
Although the majority of these key data points scored highly, only 19 countries had all three of these 
key prevalence parameters scored as moderate or better, whilst 66 countries have at least two of 
these parameters scored moderate or better. These 19 and 66 countries account for 32% and 76% of 
the global population, respectively. It is possible that the PAF projections for the remaining countries 
may change when better data becomes available, with better data being most needed for the HCV 
prevalence in the general population and the size estimates of PWID populations. When only 
considering the 66 countries with better data, the global average PAF increases slightly to 49% (95% 
CrI: 29%-73%) emphasising that not including projections from the countries with worse quality data 
does not substantially affect our projections. 
Additionally, some country’s tPAF estimates were lower than expected, including Spain (31%), 
Greece (23%), and Australia (62%); previous evidence for these countries has suggested most 
transmission was among IDU5. This discrepancy may be due to data issues, or HCV-epidemic factors, 
such as historically high levels of IDU that have now decreased, under-estimates of PWID 
prevalence, or possibly high numbers of migrants with higher HCV risk than the background 
population. Other modelling from the Netherlands has suggested that most HCV infections were 
among migrants28. We did not incorporate migration in our model due to insufficient data to do this 
and uncertainty around key assumptions, such as their HCV prevalence.30 Although not explicitly 
included, we would consider incoming infections due to migration as something that contributes to 
the non-IDU transmission aspect of the model, just as we would for medical and community 
transmission. Similarly, we were unable to include HCV epidemics among MSM within our model 
due to a scarcity of information around prevalences globally. However, studies indicate that 
although transmission among MSM is much higher than among heterosexual couples, incidence and 
prevalence is still low compared with PWID31 and likely contributes little to the epidemic in 
comparison32. 
We also did not explicitly model what makes up the non-IDU component of HCV transmission, which 
could be due to medical injections, tattooing, body-piercing, barbering, etc. Unfortunately, detailed 
country-level data on these behaviours were unavailable. Despite these issues, other country-level 
estimates seem to agree with our model28,29, with the low tPAFs of IDU in some HICs implying that 
our global tPAF estimate for IDU may be conservative. Also, general insights about how the tPAF is 
related to different country-level factors should still hold.  
Another limitation of our analysis is that our deterministic models did not capture the network 
effects of how HCV transmits among PWID, which has been shown to be important for assessing the 
impact of interventions for HCV33,34. This paper is less concerned in this question, rather its main aim 
is to determine how the observed epidemic among PWID may contribute to overall levels of 
transmission in that country.  
  
For almost all countries included, there is little to no published data to determine the likely ongoing 
evolution of each country’s HCV epidemic. To counter this, we gathered available evidence on 
reductions in HCV transmission risks due to improved blood transfusion safety22 or reductions in 
unsafe medical injections23, and so assumed that the modelled global epidemic was in decline, 
consistent with modelling by Blach et al2. However, there is considerable uncertainty in this 
assumption, so we assumed wide uncertainty bounds and undertook sensitivity analyses where we 
either assumed each country’s HCV prevalence trends were stable or varied by region, which both 
projected lower tPAFs (about 30-33%). Importantly, country-level HCV epidemic trajectories are 
highly uncertain with only three countries having two repeated national surveys, highlighting the 
need for further data on this. Additionally, the systematic reviews used for this analysis, although 
from 2017, lacked data from recent years where HCV outbreaks have occurred among PWID in some 
countries, notably USA26 where a higher tPAF is estimated when this is assumed. The lack of robust 
data on HCV prevalence, especially for the general population, also raises concerns about whether 
countries will be able to reliably ascertain their progress towards WHO’s HCV elimination targets or 
develop plans to reach them. This highlights the crucial role of good data for policy-making. 
Importantly, a single inaccurate data point could affect a country’s results, implying that careful 
consideration of the assumptions made is required before using our results to inform policy in 
specific countries.  
Despite the limitations described above, it is also important to note that this paper utilises data from 
12 reviews, synthesising data from thousands of studies and accounting for the uncertainty in these 
estimates in our projections. This will have minimised the data issues as far as is currently possible, 
with our extensive sensitivity analyses showing that the overall finding that IDU is an important 
contributor to the global HCV epidemic is robust despite data uncertainties.  
Implications  
To our knowledge, this is the first study to fully quantify the future contribution of IDU to the global 
HCV epidemic. The results show that the elevated risks associated with IDU account for 43% of 
global HCV infections over the next 12 years; with this figure being even higher in HICs (79%). This 
information is primarily useful for policy-makers that are uncertain about the importance of 
combating the HCV epidemic amongst PWID, especially for meeting the WHO’s 2030 elimination 
targets3. Indeed, globally, our results suggest the incidence of HCV in PWID needs to be reduced by 
at least half to have any hope of reducing the overall incidence of HCV by 80%. Such a reduction in 
incidence can be achieved through reducing prevalence or transmission risks, including via micro 
elimination initiatives that either scale-up HCV treatment for PWID or prevention interventions35, 
such as needle and syringe provision (NSP) and OST programs. Newly synthesised data and 
modelling has shown that these interventions can dramatically reduce levels of HCV incidence26,36, 
can be cost-effective in various settings36,37, and can also prevent other blood-borne viruses such as 
HIV38. However, the current coverage of NSP and OST is low in most countries,39 as is the coverage of 
direct acting antiviral drug treatment40, with PWID being frequently denied treatment41. Barriers 
restricting the coverage of these interventions need to be urgently addressed to achieve the WHO 
HCV elimination targets.  
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Figure 1: Schematic of model showing how people move through the seven age and injecting drug 
use compartments. PWID denotes people who inject drugs. 
 
Figure 2: Regional and global estimates for the Population Attributable Fraction (tPAF) of the risks 
associated with injecting drug use (IDU) to Hepatitis C virus (HCV) transmission from 2018-2030. 
Medians shown in bars, with 95% credibility intervals shown with red lines.  
  
  
  
Figure 3: Map of Population Attributable Fraction (tPAF) of HCV transmission due to the risks 
associated with IDU from 2018-2030. This was calculated as the percentage of all new HCV infections 
that would be prevented over 2018-2030 if the additional transmission risk due to IDU was removed 
over this period. Countries in grey were not modelled due to a lack of data. 
  
 
 
  
  
Figure 4: Bar chart of each country’s population attributable fraction (tPAF) of the risks associated 
with injecting drug use to hepatitis C virus (HCV) transmission 2018-2030 against the percentage of 
the global prevalent HCV infections (2017) in that country. Countries with the largest chronic HCV 
burdens in 2017 are labelled. 
 
 
  
  
Figure 5: Scatter plot of the association between the Population Attributable Fraction (tPAF) of the 
risks associated with injecting drug use (IDU) to Hepatitis C virus (HCV) transmission from 2018-2030 
and the percentage of the country’s prevalent infections that are among PWID in 2017 for each 
country (the red dots). The blue line is a plotted line of best fit* and the grey area is the 95% 
confidence interval.  
 
  *Model 
equation: tPAF=-0.3149-(0.0372*P_PWID)+(0.4376*P_PWID1/2), where P_PWID is the percentage of 
the country’s prevalent infections that are among PWID 
  
Table 1: Regional averaged fitted prevalence estimates in 2017, and model projections of the Population Attributable Fraction (tPAF) of injecting drug use 
(IDU) to Hepatitis C virus (HCV) transmission from 2018 to 2019 (1-year tPAF) and 2030 (12-year tPAF) – all with 95% credibility intervals. We also give the 
percentage of that setting’s prevalent infections in 2017 that are amongst PWID to compare with the tPAF. The tPAF is defined as the percentage of all new 
HCV infections that would be prevented if the transmission risk due to IDU was removed over this period. 
  Fitted demographic data values 
Percentage of the 
setting’s prevalent 
infections that are 
among PWID 
tPAF of HCV infections due to IDU 
Country 
% of Adults that are 
PWID 
Chronic HCV prevalence 
(%) among PWID 
Chronic HCV 
prevalence (%) 
among general 
population 
  
2018-2019 2018-2030 
Global 0.32 (0.23, 0.42) 34.5 (25.8, 42.0) 1.0 (0.7, 1.4) 8 (5, 12) 39% (21%, 64%) 43% (25%, 67%) 
Central Asia 0.61 (0.44, 0.81) 26.4 (21, 29.8) 2.4 (1.5, 3.3) 4 (3, 6) 32% (16%, 69%) 37% (19%, 73%) 
Eastern Europe 1.13 (0.71, 1.61) 45.8 (34.0, 53.6) 2.0 (1.2, 2.6) 21 (12, 31) 95% (64%, 99%) 96% (69%, 99%) 
Australasia 0.60 (0.46, 0.73) 35.7 (32.0, 39.3) 0.8 (0.7, 1.1) 19 (13, 24) 58% (34%, 94%) 66% (43%, 96%) 
East & Southeast Asia 0.23 (0.19, 0.28) 31.5 (23.8, 38.2) 0.7 (0.5, 1.0) 7 (5, 10) 53% (26%, 98%) 58% (32%, 98%) 
South Asia 0.09 (0.07, 0.11) 30.3 (16.2, 44.0) 0.9 (0.6, 1.3) 2 (1, 3) 10% (3%, 25%) 14% (4%, 31%) 
North America 1.08 (0.63, 1.51) 30.7 (22.2, 40.7) 0.9 (0.6, 1.2) 30 (16, 47) 67% (43%, 100%) 77% (56%, 100%) 
Western Europe 0.32 (0.23, 0.40) 37.9 (27.3, 44.7) 0.6 (0.3, 1.0) 15 (10, 20) 80% (45%, 93%) 83% (53%, 94%) 
Sub Saharan Africa 0.40 (0.26, 0.55) 14.2 (10.5, 17.7) 1.4 (0.9, 2.2) 3 (1, 4) 11% (2%, 39%) 14% (2%, 43%) 
Latin America 0.44 (0.35, 0.53) 49.7 (44.1, 52.8) 0.8 (0.7, 1.0) 18 (14, 23) 66% (41%, 98%) 71% (49%, 98%) 
Middle East & North 
Africa 0.24 (0.17, 0.30) 31.7 (23.6, 36.8) 2.5 (2.0, 3.1) 2 (1, 3) 13% (6%, 25%) 16% (8%, 28%) 
  
Table 2: Univariable and multivariable coefficients (with 95% confidence intervals) of the 
associations between the Population Attributable Fraction (tPAF) of injecting drug use to Hepatitis C 
virus (HCV) transmission from 2018-2030, logit transformed, and demographic and epidemic-related 
variables. The tPAF is defined as the percentage of all new HCV infections that would be prevented 
over 2018-2030 if the additional transmission risk due to IDU was removed over this period. 
 Dependent variable: tPAF (logit transformed) 
 Coefficient (95% confidence interval) 
Variable* Univariable Multivariable 
GNI per capita (per $1000)** 0.05 (0.00, 0.10) [p=0.039] 0.01 (-0.04, 0.07) [p=0.64] 
Population percentage of PWID in adults 2.62 (0.75, 4.49) [p=0.0066] 1.14 (-1.21, 3.50) [p=0.34] 
HCV prevalence among PWID*** 0.09 (0.02, 0.17) [p=0.014] 0.05 (-0.02, 0.12) [p=0.12] 
HCV prevalence among general population*** -0.29 (-1.34, 0.75) [p=0.58] -0.07 (-1.28, 1.13) [p=0.903] 
Injecting duration (years) 0.21 (-0.00, 0.42) [p=0.053] -0.22 (-0.46, 0.02) [p=0.071] 
Percentage of the country’s prevalent infections 
that are among PWID 
0.26 (0.18, 0.34) [p<0.0001] 0.26 (0.13, 0.38) [p<0.0001] 
GNI: Gross National Income 
*All variables are from 2017 except for injecting duration which is taken from surveys covering a 
variety of years for each country. 
**Syria is missing data on GNI per capita. 
*** HCV prevalence measures are proportions, not percentages 
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